Laxmi Organic Industries (LXCHEM) Q3 24/25 earnings summary

Executive summary

• Achieved double-digit year-over-year growth in volumes, revenue, and EBITDA for Q3 and the first nine months, driven by operational excellence, capacity expansion, and customer-centric strategies.

• Maintained stable demand across pharma, coatings, printing, packaging, and flavors/fragrances; agro segment remains weak but is expected to recover.

• Received a credit rating upgrade to AA/Stable/A1+ and significant improvement in sustainability ratings.

• Board and Audit Committee reviewed and approved consolidated and standalone financial results, with no material misstatements found by auditors.

• Company operates as a single segment, 'Chemical Business,' for reporting purposes.

Financial highlights

• Q3FY25 consolidated revenue rose 13% year-over-year to ₹7,863.35 million; 9MFY25 revenue up 10% to ₹22,757.55 million.

• Q3FY25 EBITDA increased 43% year-over-year to ₹748 million; 9MFY25 EBITDA up 31% to ₹2,206 million.

• Q3FY25 PAT grew 8% year-over-year to ₹293.08 million; 9MFY25 PAT up 20% to ₹917.45 million.

• Gross margin improved by 240 bps to 33.1% in Q3FY25 and by 320 bps to 34.8% in 9MFY25.

• Export sales improved to 36% of total sales, aiding currency risk mitigation.

Outlook and guidance

• Targeting to double consolidated revenue and triple EBITDA by FY28, with a combined ROCE of 20%.

• CapEx of INR 11,000 million planned through FY28, with major spend in Dahej and Lote projects; sales expected to double by FY 2028.

• Fluoro-intermediates site expected to generate revenue from Q4FY25; Dahej and Lote projects progressing on schedule.

• Specialty business expected to maintain 20%-25% EBITDA margin as fluoro intermediates ramp up to 40%-60% of peak revenue by FY 2026.

• The company is pursuing a merger with its wholly owned subsidiary Yellowstone Fine Chemicals Pvt Ltd, pending NCLT approval.